Trinomab Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Zhuhai Guangdong China

Primary Industry

Biotechnology

About

Established in 2015 and based in Zhuhai, China, Trinomab is a biopharmaceutical company engaged in the R&D of novel fully native human monoclonal antibody (mAb) drugs. The Chairman and CTO, Huaxin Liao, graduated from Shanghai Medical University. The CEO and President, Weihong Zheng, was the General Manager of Oasis Pharmaceutical Co., Ltd. In November 2022, TNM002 entered Phase III clinical trial. In April 2021, the antibody production base in Zhuhai International Health Port was completed and put into operation.In April 2023, Trinomab raised approximately CNY 200 million in strategic investment from new investors Kangjun Capital, Huajin Securities, Fresscon Capital, China Science & Merchants Capital Management, and China Medical System Holdings. The company is developing multiple product pipelines. Those new drugs will be used for prevention of respiratory syncytial virus (RSV) infection, prevention of tetanus, herpes zoster virus, hCMV infection, arthralgia, bacterial infectious shock, and rabies prevention. Those drugs' development is based on the self-developed human monoclonal antibodies (Hitmab) platform.

Current Investors

Zhuhai Jinhang Industrial Investment, Wuxi Guolian Industrial Investment Private Equity Fund Management, Glory Ventures

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Bioinformatics, Healthcare IT, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.trinomab.com

Verticals

HealthTech, Manufacturing

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.